Biotechnology

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...

2022-03-18 22:12 5788

Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests

SHANGHAI, March 18, 2022 /PRNewswire/ -- At present, COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants are rampant, resulting in the continuous enhancement of their transmission ability. Amid the repeated waves of COVID-19, in addition to COVI...

2022-03-18 17:47 1671

WH Group's Subsidiary Smithfield Foods Partners with BioCircuit Technologies to Deliver Innovative Nerve Repair Solution

HONG KONG, March 18, 2022 /PRNewswire/ -- WH Group Limited ("WH Group" or "the Company", HKEX stock code: 288) today announced that Smithfield BioScience, a unit of WH Group's subsidiary Smithfield Foods which delivers life-saving medical solutions from porcine-derived bioproducts, and BioCircuit...

2022-03-18 16:31 2221

CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the global multi-regional ...

2022-03-18 08:37 2935

HitGen Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, March 17, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company (688222.SH) HitGen Inc. ("HitGen") today announced that it has entered into a research collaboration agreement with Howard Hughes Medical Institute ("HHMI") andDuke University. The Principal Investigators for HH...

2022-03-17 22:30 1886

China CDE Approved First Universal CAR-T IND !

NANJING, China, March 17, 2022 /PRNewswire/ -- On March 17, 2022, China National Drug Administration Drug Review Center (CDE) approved first Universal Chemeric Antigen Receptor T (UCAR-T) cell drug (Acceptance No. : CXSL2101509). CTA101 is independently developed by Nanjing Bioheng Biotech Co., L...

2022-03-17 21:32 1525

Triastek and Siemens announce strategic collaboration to accelerate digital transformation of the pharmaceutical industry

NANJING, China, March 17, 2022 /PRNewswire/ -- Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies a...

2022-03-17 21:24 2212

Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary

SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment ofGlen Hansen, Ph.D., D(ABMM), FCCM, as the Head of Scientific and Medical Affairs of itsUnited States subs...

2022-03-17 20:00 1351

KeyZell start-up plans to reach 5 million euros in private investment and become the new biotech unicorn

MADRID, March 17, 2022 /PRNewswire/ -- KeyZell, a Spanish biotechnology company in the development phase of digital cancer treatments and tools, has just opened a private financing round which expects to achieve5 million euros to boost its projects and consolidate itself as one of the biotech sta...

2022-03-17 15:30 2459

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...

2022-03-17 08:00 2983

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...

2022-03-16 23:46 1812

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement withColumbia University ("Columbia") and...

2022-03-16 20:38 2353

Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies

- Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities - HANGZHOU, China and ROCKVILLE, Md., March 16, 2022 /PRNewswire/ -- Innoforce, a global development and biomanufacturing company focused on Advanced Therapy Medic...

2022-03-16 19:00 1624

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase1b/2 clinical trial of its anti-CTLA-4 monoclonal antib...

2022-03-16 19:00 2322

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK

COPENHAGEN, Denmark, March 16, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Jasper Clube as Chief Intellectual Property Officer from 1 February 2022 and Stephanie Krebs as Chief Business Officer from 14 March 2022. ...

2022-03-16 14:28 1566

Gene Solutions Makes Earlier Detection of Cancer A Possibility of the Future

HO CHI MINH CITY, Vietnam, March 16, 2022 /PRNewswire/ -- The scientific research team fromGene Solutions  has invented a SPOT-MAS liquid biopsy technology to enhance early-stage detection of many cancers. This technology is to expect to reshape the landscape of early c...

2022-03-16 09:36 2733

European Wellness Biomedical Group and AK International to Bring Biological Regenerative Medicine Solutions to Pakistan and UAE

DUBAI, UAE, March 15, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has signed a Memorandum of Agreement (MOA) withDubai-based AK International LLC (AKI), partnering together to undertake a number of joint venture businesses inPakistan and the MENA region that focus on providing ...

2022-03-15 08:00 2604

I Peace triples GMP cell manufacturing by expanding CDMO facility

PALO ALTO, Calif., March 14, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.The facility's expansion, ...

2022-03-15 03:22 1508

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 14, 2022 /PRNewwire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announc...

2022-03-15 00:06 1773

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of aUS$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highligh...

2022-03-14 20:50 1936
1 ... 145146147148149150151 ... 279